EANS-News: SYGNIS Pharma AG / SYGNIS announces six months results of fiscal year 2012

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

6-month report

Heidelberg (euro adhoc) - SYGNIS announces six months results of
fiscal year 2012

Heidelberg, November 14, 2012 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) today reports its financial
results for the six months period ended September 30, 2012.

Financials

- The net loss in the second quarter was EUR-1.3 million
(EUR-2.0 million Q2 2011/2012). The net loss for the six months period
was EUR-2.5 million(EUR-3.3 million H1 2011/2012)
- Total operating expenses for the first six months were down at
EUR 2.6 million (EUR4.3 million first half 2011/2012).
- Cash including marketable securities amounted to EUR1.9 million as
of September 30, 2012 (EUR8.1 million September 30, 2011).

Operational summary

- In July 2012 SYGNIS implemented essential transaction steps as part of the
necessary realignment. These steps included the signing of the Term Sheet
regarding the merger with X-Pol Biotech S.L. (X-Pol) and the early
prolongation of the SEDA agreement.
- Moreover SYGNIS was informed in September 2012 about the fact that the
German Federal Financial Supervisory Authority (BaFin) has granted
Genetrix an exemption from the obligations according to § 35 WpÜG
(Securities Acquisition and Takeover Act), in particular to provide a
mandatory offer to the shareholders of SYGNIS. This exemption is a
prerequisite for the successful implementation of the business combination
with X-Pol.
- The operating expenses and the liquidity outflow during the first six
months of the fiscal year were within the expectations of the Company.
- Within the KIBRA project further progress has been achieved on the way of
identifying lead compounds. In addition the Company has intensified the
partnering process by numerous discussions with potential partners.

Significant events after the balance sheet date

- In connection with the realignment of the Company, the Board member Dr.
Frank Rathgeb has resigned from the Management Board of SYGNIS by mutual
agreement with the Supervisory Board on 31 October 2012.

- Representing 73% of the voting share capital the shareholders of SYGNIS
agreed to all items of the agenda in the Annual Shareholder Meeting. These
items primarily include the following measures:

- Resolution on the reduction of the share capital of the Company from
EUR 16,829,504 to EUR 2,103,688 by consolidating shares in a 8:1 ratio
- Capital increase against contribution in kind from EUR 2,103,688
to EUR 9,349,724 by contribution of all shares of X-Pol
- Election of the new Supervisory Board
- Change of fiscal year to the calendar year and constituting a
short year from 1 April to 31 December 2012

- Subsequently to the Shareholders' Meeting on 17 October 2012 the
Supervisory Board has appointed Mrs. Pilar de la Huerta to the Management
Board of the Company and has nominated her as CEO.

Outlook

- For the upcoming months emphasis is being placed on securing sufficient
funding and the realignment of the Company through the business
combination with X-Pol. With the marketing of the DNA amplification
technologies and products, SYGNIS is aiming to generate initial revenues
and to establish a profitable business in the medium term.
- For the KIBRA project, the partnering process is ongoing. However, should
the Company not succeed in winning a partner for KIBRA, the Management
Board will have to reconsider the future of this project.
- The Company's available funds as of 30 September 2012 secure the liquidity
of SYGNIS until approximately March 2013. To further finance its business
activities, the Company will have to rely on further funding from March
2013 on.

|Key financial figures for the second quarter of short fiscal year |
|2012 ended September 30, 2012 and corresponding figures (IFRS) |
|Numbers in million euros |Q2 2012 |Q2 2011/2012 |
|Revenues |0.1 |0.0 |
|Total expenses |1.3 |2.1 |
|EBIT |-1.2 |-2.1 |
|Net results for the period |-1.3 |-2.0 |
|Intangible assets |2.2 |20.5 |
|Liquidity at end of quarter |1.9 |8.1 |
|Equity |3.5 |19.4 |
|(equity ratio in %) |(60) |(59) |
|Long-term financial liabilities |0.0 |8.0 |
|Operating Cash Flow |-1.2 |-2.5 |

|Key figures for the first six months of short fiscal year 2012 |
|ended September 30, 2012 and comparables (IFRS) |
|Numbers in million euros |H1 2012 |H1 2011/12 |
|Revenues |0.1 |0.2 |
|Total expenses |2.6 |4.3 |
|EBIT |-2.5 |-4.2 |
|Net results for the period |-2.5 |-3.3 |
|Operating cash flow |-2.5 |-4.5 |

The report on the first six months of the short fiscal year 2012
which ended on September 30, 2012 is available at the SYGNIS webpage
at www.sygnis.de.

About SYGNIS Pharma AG: www.sygnis.de SYGNIS Pharma AG
(Heidelberg, Germany) is currently a specialty drug
development company, focusing on innovative treatments for
underserved human diseases. Early in 2012 the company decided to
discontinue its Phase II lead program AX200 in stroke. While the
company continued research activities in the field of cognitive
disorders, it started at the same time a systematic M&A
process, to add new operational assets and activities to SYGNIS
Pharma AG. SYGNIS Pharma AG is listed in the Prime Standard of
the Frankfurt Stock Exchange under the ticker: LIOK; and ISIN:
DE000A1E9B74.

About X-Pol Biotech, S.L.: www.xpolbiotech.com X-Pol Biotech, S.L.
(Madrid, Spain) is a biotechnology company created by Prof.

Luis Blanco and GENETRIX in 2008 with a focus on the development of tools and
technologies for the DNA amplification and sequencing market. In July 2012 X-
Pol has licensed its key product, an improved polymerase for amplifying DNA
called "Qualiphi®" to Qiagen for its worldwide commercialisation.

For further information please contact:

|
|Peter Willinger |
|CFO
|
|SYGNIS Pharma AG |
|Tel.: +49 6221 454836
|E-mail: peter.willinger@sygnis.de

### Disclaimer
Some statements included in this press release, relating neither to proven

financial results nor other historical data, should be viewed
as forward- looking, i.e. not definite. Such statements are mainly
predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the
light of new information or future results or for any other
reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English